• Research

    New Vaccine Treatment for GNAS

    Researchers from Oslo, Norway have released a new paper outlining the potential for use of a peptide vaccine to help patients with PMP exhibiting mutation in GNAS. They write: “Patients with GNAS-mutated pseudomyxoma peritonei (PMP) have a pre-existing immunity against mutated Gsa. Inhibition of anti-tumor T-cells by upregulation of immune checkpoint molecules results in insufficient immune response. The results suggest exporint peptide vaccination with Gsa peptides in combination with immune checkpoint inhibition as a possible curative treatment for PMP and other GNAS-mutated cancers.”     You can read this new paper here.

  • Research

    Ki-67 shows great potential as a stratification biomarker

    The identifiation of patients who may require a specific treatment for PMP has long been one of the largest challenges facing doctors. Researchers from Spain’s Reina Sofia University Hospital and Maimonides Institute for Biomedical Research of Cordoba (IMIBIC) have published a new paper looking at the potential for use of the tumour proliferation protein Ki-67 as a potential biomarker of disease severity. EuroPMP members Alvaro Arjona-Sanchez and Antiono Romero-Ruiz noted that patients with high grade PMP associated with a high proliferative index in Ki-67 (over 15%) were more likely to suffer from a worse prognosis overall than patients with lower levels of this key proliferation protein. The inclusion of this…

  • Research

    Antiproliferative activity of vorinostat

    Researchers from the EuroPMP COST Action have recently published a new article looking at the antiproliferative activity of vorinostat in PMP-like cell lines. Members from Greece (Christiana Mantzourani and George Kokotos) and Finland (Pirjo Nummela and Ari Ristimäki) collaborated on this project to shed new light on the potential use of antitumor agents to treat pseudomyxoma peritonei. George notes: “We have shown that one of these new analogs showed antiproliferative activity against two colon cancer cell lines genetically resembling pseudomyxoma peritonei (PMP), namely HCT116 GNAS R201C/+ and LS174T (IC50 0.6 and 1.4 μМ, respectively) with potency slightly better than vorinostat (IC50 1.1 and 2.1 μМ, respectively).” We congratulate Finland and…

  • Research

    New paper suggests the value of anti-angiogenic treatments

    There is a lot of evidence to suggest anti-angiogenic treatment (treatments that stop new blood vessels from growing) might be helpful in treatment for Pseudomyxoma peritonei. A new paper from the Oslo team suggests that angiogenesis may be a larger factor in PMP progression than previously thought. Although research is still in the early stages, this research suggests that the potential for anti-angiogenic treatment warrants further study. The new paper may be read here. (Image: Wikimedia Commons)

  • Research

    The Role of EM Plasticity in PMP

    EuroPMP members from Venice, Italy, Maria Luisa Calabrò and Antonio Sommariva, have recently published a new paper on the role of epithelial-mesenchymal plasticity in PMP. This is a very interesting paper that looks at a part of the PMP picture that is still not well-understood, namely the way in which cells move from the first site they grow in to other sites around the abdominal cavity. Dr Calabrò states: “This review focuses on the role of epithelial-mesenchymal dynamics leading to the dissemination and growth of appendix mucinous neoplasms in the peritoneum. We mainly discuss factors and pathways involved in the pathogenesis of PMP highlighting the plasticity of PMP cells, a…

  • Research

    New Review Examines Current Research Strategies

    Researchers Christin Lund-Andersen, Annette Torgunrud, Karianne Giller-Fleten (shared first-authors) and P.I. Kjersti Flatmark have published an extensive review article looking at the use of high-throughput -omics analysis in the search for a cure for peritoneal metastases from colorectal cancer (PM-CRC) and pseudomyxoma peritonei (PMP). The study looked at molecular approaches including genomic, transcriptomic and proteomic analyses, and tumour enrichment strategies to determine whether there are any patterns in the data that could potentially assist in the management of patients with PM-CRC or PMP. The findings indicate that while there are many potential areas to focus on in the research environment, there is a strong indication that the best way forward…

  • Research

    New study looks at efficacy of Neoadjuvant Intraperitoneal Chemotherapy in Unresectable PMP Patients

    EuroPMP member Andreas Brandl has recently, in collaboration with Yutaka Yonemura, published a new paper looking into the efficacy of neoadjuvant intraperitoneal chemotherapy in patients who were not candidates for cytoreductive surgery at the time of diagnosis. The study showed low morbidity and mortality when neoadjuvant intraperitoneal chemotherapy was given to patients, and appears to show a higher rate of complete cytoreduction compared to the traditional treatment afforded these patients. The study is still ongoing and will report on the long-term survival characteristics of these and more patients in the future. The new paper may be read here.

  • Research

    New Paper from Finland – Altered linkage pattern of N-glycan sialic acids in PMP

    All human cells are covered by sugar coating, mostly consisting of glycan structures attached to proteins and lipids, and this coating frequently shows alterations in tumor cells. In their new publication, Finland’s Pirjo Nummela, Anna Lepistö and Ari Ristimäki have analyzed the profiles of a specific class of glycans, sialylated N-glycans, in PMP tissues compared to both normal appendices and the original appendix tumors (LAMNs). According to their results, PMPs present increased expression of glycans able to function as ligands of Siglecs and selectins, which may play a role in the peritoneal dissemination and progression of the disease. Further, the glycan profiles of PMPs suggest that the process of its…

  • Research

    Incidence and Prevalence in Europe

    EuroPMP member researchers from Norway and the United Kingdom have recently published a paper giving a sound scientific footing for the incidence and prevalence of PMP in Europe. The research suggests that the previous incidence estimate of 1-2 persons per million is too low, with a more realistic figure being around 3.2 persons per million. The prevalence was estimated to be around 22 persons per million in Europe, meaning 11,726 people living with active disease in 2018. The incidence and prevalence paper can be read here.  

  • Research

    Individual Efficacy of Drug Therapies in Xenograft Models

    Norway’s Karianne Giller Fleten, Christin Lund-Andersen, Annette Torgunrud and Kjersti Flatmark have published a new paper that looks into the individual efficacy of four drug therapies on peritoneal metastases in mouse-human xenograft models: oxaliplatin, irinotecan, cabazitaxel, and regorafenib and capecitabine. The results support the continued exploration of intraperitoneal treatment protocols for peritoneal metastases with oxaliplatin remaining and cabazitaxel emerging as the most interesting candidates for further studies. You can read the new paper here.